P1.04-26 EMT-Associated Response and Resistance to MEK Inhibitor and Immune Checkpoint Blockade Combinations in KRAS-Mutant NSCLC

MLA

Limo Chen, et al. “P1.04-26 EMT-Associated Response and Resistance to MEK Inhibitor and Immune Checkpoint Blockade Combinations in KRAS-Mutant NSCLC.” Journal of Thoracic Oncology, vol. 14, Oct. 2019, pp. S449–50. EBSCOhost, https://doi.org/10.1016/j.jtho.2019.08.929.

APA

Limo Chen, Bertha Leticia Rodriguez, Jennifer A. Wargo, David H. Peng, Don L. Gibbons, Jared J. Fradette, Laura A. Gibson, Samrat T. Kundu, Pierre Olivier Gaudreau, Triparna Sen, & C.M. Della Corte. (2019). P1.04-26 EMT-Associated Response and Resistance to MEK Inhibitor and Immune Checkpoint Blockade Combinations in KRAS-Mutant NSCLC. Journal of Thoracic Oncology, 14, S449–S450. https://doi.org/10.1016/j.jtho.2019.08.929

Chicago

Limo Chen, Bertha Leticia Rodriguez, Jennifer A. Wargo, David H. Peng, Don L. Gibbons, Jared J. Fradette, Laura A. Gibson, et al. 2019. “P1.04-26 EMT-Associated Response and Resistance to MEK Inhibitor and Immune Checkpoint Blockade Combinations in KRAS-Mutant NSCLC.” Journal of Thoracic Oncology 14 (October): S449–50. doi:10.1016/j.jtho.2019.08.929.